FDA Launches Nader Program for Rare Disease Drugs
The General Authority for Food and Drug Authority in the Kingdom has launched the "Nader" program to support and develop drugs for rare diseases, aiming to accelerate access to these medicines for patients. The program targets pharmaceutical products that treat or prevent rare diseases with an incidence rate of fewer than five cases per 10,000 people, which lack effective treatments or offer therapeutic benefits that surpass current options. These products may be in the development stages or have external approvals without registration within the Kingdom. Support includes providing flexible regulatory and scientific facilitations, adopting innovative methods to demonstrate efficacy, and implementing flexible procedures for manufacturing registration, all within the framework of Saudi Arabia’s Vision 2030 to enhance citizens’ quality of life and improve healthcare.
Notice: This Is an AI-Generated Summary
Comments (0)